Michel Dahan
Net Worth
Last updated:
What is Michel Dahan net worth?
The estimated net worth of Mr. Michel Dahan is at least $8,550,765 as of 13 May 2024. He owns shares worth $2,056,602 as insider, has earned $597,903 from insider trading and has received compensation worth at least $5,896,260 in Akebia Therapeutics, Inc..
What is the salary of Michel Dahan?
Mr. Michel Dahan salary is $655,140 per year as Senior Vice President & Chief Operating Officer in Akebia Therapeutics, Inc..
How old is Michel Dahan?
Mr. Michel Dahan is 46 years old, born in 1979.
What stocks does Michel Dahan currently own?
As insider, Mr. Michel Dahan owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Akebia Therapeutics, Inc. (AKBA) | Senior Vice President & Chief Operating Officer | 672,092 | $3.06 | $2,056,602 |
What does Akebia Therapeutics, Inc. do?
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Michel Dahan insider trading
Akebia Therapeutics, Inc.
Mr. Michel Dahan has made 25 insider trades between 2016-2024, according to the Form 4 filled with the SEC. Most recently he sold 34,840 units of AKBA stock worth $43,898 on 13 May 2024.
The largest trade he's ever made was exercising 95,478 units of AKBA stock on 25 May 2023. As of 13 May 2024 he still owns at least 672,092 units of AKBA stock.
Akebia Therapeutics key executives
Akebia Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Steven Keith Burke (64) Senior Vice President of R&D and Chief Medical Officer
- Mr. David A. Spellman (48) Senior Vice President, Chief Financial Officer & Treasurer
- Mr. Dell Faulkingham (52) Senior Vice President & Chief Commercial Officer
- Mr. Jason A. Amello (57) Executive Officer
- Mr. John P. Butler MBA (61) Chief Executive Officer, Pres & Director
- Mr. Michel Dahan (46) Senior Vice President & Chief Operating Officer